{"id":70759,"date":"2026-05-12T10:48:03","date_gmt":"2026-05-12T10:48:03","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70759"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"survodutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/survodutide\/","title":{"rendered":"Survodutide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 Survodutide?<\/h3>\n<p style=\"margin: 0;\"><strong>Survodutide<\/strong> (developmental code BI 456906) is a 29-amino-acid long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. In published Phase 2 studies it produced striking effects in MASH (metabolic-dysfunction-associated steatohepatitis) liver fibrosis alongside obesity body-weight reductions of ~19% over 46 weeks. Plasma half-life supports once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2230198-02-2 (survodutide; comumente citado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Co-agonista dual de receptor GLP-1\/glucagon de a\u00e7\u00e3o prolongada (pept\u00eddeo sint\u00e9tico acilado; Boehringer Ingelheim BI 456906; co-desenvolvido com Zealand Pharma)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~3.800 Da (com acila\u00e7\u00e3o de \u00e1cido graxo; forma pept\u00eddica madura)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estrutura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pept\u00eddeo sint\u00e9tico co-agonista de 29 amino\u00e1cidos com substitui\u00e7\u00f5es Aib projetadas para resist\u00eancia \u00e0 DPP-4 e uma cadeia acilada de \u00e1cido graxo acoplada a um res\u00edduo de lisina via um ligante \u03b3-Glu. Substancialmente mais curto que os agonistas duais derivados da oxintomodulina (mazdutide ~39 aa), preservando a atividade dual equilibrada nos receptores GLP-1\/glucagon.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (branco a branco amarelado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA sob solicita\u00e7\u00e3o)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (geladeira) para estoque de trabalho; \u221220 \u00b0C para armazenamento de longo prazo de frascos fechados. Reconstitu\u00eddo: 2\u20138 \u00b0C, usar em at\u00e9 ~30 dias. Proteger da luz. N\u00e3o congelar e descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para janelas de uso mais curtas. Pept\u00eddeos acilados podem dissolver mais lentamente \u2014 permita tempo extra de equil\u00edbrio.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 Survodutide?<\/h2>\n<p><strong>Survodutide<\/strong> (developmental code BI 456906) is a long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. It represents the Western pharmaceutical arm of the dual GLP-1\/glucagon co-agonist studies programme, alongside the parallel programmes that produced <a href=\"https:\/\/medsbase.com\/pt-br\/mazdutide\/\">mazdutide<\/a> (Innovent Biologics, China) and the older Pegapamodutide \/ Cotadutide compounds. Survodutide is structurally compact \u2014 just 29 amino acids \u2014 substantially shorter than the oxyntomodulin-derived dual agonists, while preserving balanced agonist activity at both target receptors through engineered substitutions and fatty-acid acylation. Survodutide has a mature molecular weight of approximately 3,800\u00a0Da including the acyl modification. The 29-residue length is one of the structural distinctives: shorter peptides are typically cheaper to synthesise per unit dose but have less surface area for fine-tuning receptor-balance pharmacology. Boehringer-Zealand achieved the dual-agonist balance through a combination of strategic Aib substitutions at DPP-4 cleavage sites and careful tuning of receptor-binding-pocket residues. Plasma half-life is approximately 6 days, supporting once-weekly subcutaneous dosing. The current clinical signature of survodutide is the <strong>efeito impressionante na fibrose hep\u00e1tica em MASH (esteato-hepatite associada \u00e0 disfun\u00e7\u00e3o metab\u00f3lica)<\/strong> relatado no estudo de Fase 2 \u2014 um resultado que o diferenciou de outros agonistas duplos e triplos com efeitos similares no peso corporal. Os dados de obesidade da Fase 2 mostraram redu\u00e7\u00f5es de peso corporal de aproximadamente 19% com 4,8 mg semanais ao longo de 46 semanas, colocando o survodutide no mesmo n\u00edvel de efeito que o tirzepatide e pr\u00f3ximo ao agonista triplo retatrutide. O survodutide est\u00e1 atualmente em ensaios de Fase 3 para obesidade (desenho de estudo no estilo SURMOUNT) e MASH. O survodutide n\u00e3o \u00e9 <strong>n\u00e3o aprovado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the sibling dual GLP-1\/glucagon co-agonist, see our <a href=\"https:\/\/medsbase.com\/pt-br\/mazdutide\/\">Mazdutide<\/a> p\u00e1gina de produto; para o agonista triplo que adiciona GIP, consulte <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a>. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Co-agonismo Duplo dos Receptores de GLP-1 \/ Glucagon com \u00canfase Hep\u00e1tica<\/h2>\n<p>O que torna o survodutide mecanicamente distinto entre os pept\u00eddeos metab\u00f3licos de duplo agonista \u00e9 a <strong>propor\u00e7\u00e3o relativamente equilibrada de pot\u00eancia GLP-1 para glucagon<\/strong> que produz tanto efeitos substanciais de gasto energ\u00e9tico (o bra\u00e7o do glucagon) quanto os efeitos can\u00f4nicos de saciedade\/glic\u00eamicos do GLP-1, com \u00eanfase particular nos resultados hep\u00e1ticos:<\/p>\n<ul>\n<li><strong>Ativa\u00e7\u00e3o do receptor GLP-1 \u2014 saciedade, secre\u00e7\u00e3o de insulina pelas c\u00e9lulas \u03b2, esvaziamento g\u00e1strico<\/strong> \u2014 O survodutide ativa o receptor GLP-1 nas c\u00e9lulas beta pancre\u00e1ticas (secre\u00e7\u00e3o de insulina dependente de glicose, supress\u00e3o de glucagon nas c\u00e9lulas alfa), nos neur\u00f4nios POMC do n\u00facleo arqueado hipotal\u00e2mico (regula\u00e7\u00e3o central do apetite) e nos aferentes vagais g\u00e1stricos (atraso no esvaziamento g\u00e1strico). Este bra\u00e7o se sobrep\u00f5e ao mecanismo do semaglutida e ao componente GLP-1 de todos os pept\u00eddeos incret\u00ednicos multiagonistas.<\/li>\n<li><strong>Ativa\u00e7\u00e3o do receptor de glucagon \u2014 mobiliza\u00e7\u00e3o de lip\u00eddios hep\u00e1ticos, gasto energ\u00e9tico, ativa\u00e7\u00e3o do tecido adiposo marrom<\/strong> \u2014 A caracter\u00edstica definidora compartilhada com <a href=\"https:\/\/medsbase.com\/pt-br\/mazdutide\/\">mazdutide<\/a> e <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">retatrutide<\/a> is glucagon-receptor agonism. In survodutide studies, this arm produces particularly strong hepatic lipid mobilisation \u2014 hepatocytes are highly enriched for glucagon receptors, and direct glucagon-pathway activation drives fatty-acid oxidation and triglyceride export. The combined effect with the GLP-1 arm&#8217;s indirect liver benefits via reduced insulin resistance produces the distinctive MASH-fibrosis signal observed in Phase 2.<\/li>\n<li><strong>Engenharia de equil\u00edbrio de receptores e a propor\u00e7\u00e3o de pot\u00eancia do duplo agonista<\/strong> \u2014 The pharmacological challenge in dual GLP-1\/glucagon co-agonism is achieving the right relative potency at each receptor. Glucagon agonism alone raises glucose; GLP-1 agonism alone produces strong glucose-lowering. The net effect depends on the in-vivo ratio of receptor occupancy at each site. Survodutide is engineered for a glucagon-favoured balance relative to mazdutide, which contributes to the stronger hepatic effects but requires more careful titration to avoid net glucose effects in early dose-escalation protocols.<\/li>\n<\/ul>\n<p>The fatty-acid acylation at a lysine residue (analogous in concept to semaglutide&#8217;s C18 acyl chain) drives reversible serum-albumin binding that produces the ~6-day plasma half-life and supports once-weekly subcutaneous dosing in clinical studies. Subcutaneous administration is the standard administration route and the only route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Survodutide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>MASLD\/MASH (doen\u00e7a hep\u00e1tica associada \u00e0 disfun\u00e7\u00e3o metab\u00f3lica)<\/strong> \u2014 hepatic triglyceride content, ALT\/AST normalisation, fibrosis-stage progression in preclinical models and clinical Phase 2 data; survodutide&#8217;s strongest signal and the basis for its dedicated MASH Phase 3 programme<\/li>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 modelos pr\u00e9-cl\u00ednicos de roedores DIO, composi\u00e7\u00e3o corporal (DEXA\/RMI), ensaios de ingest\u00e3o alimentar, medi\u00e7\u00e3o de gasto energ\u00e9tico<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 controle glic\u00eamico, din\u00e2mica de supress\u00e3o de glucagon, substitutos de HbA1c; o equil\u00edbrio de receptores projetado favorece a redu\u00e7\u00e3o l\u00edquida da glicose, apesar do componente de glucagon<\/li>\n<li><strong>Energy-expenditure and thermogenesis studies<\/strong> \u2014 gasto energ\u00e9tico em repouso, ativa\u00e7\u00e3o do tecido adiposo marrom, express\u00e3o de genes termog\u00eanicos; particularmente relevante considerando o eixo do glucagon<\/li>\n<li><strong>Comparative dual-agonist studies<\/strong> \u2014 compara\u00e7\u00e3o direta com o co-agonista alternativo GLP-1\/glucagon <a href=\"https:\/\/medsbase.com\/pt-br\/mazdutide\/\">Mazdutide<\/a> (derivado da oxintomodulina, 39 aa), o duplo GLP-1\/GIP <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">Tirzepatide<\/a>, e o triplo-agonista <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a>; receptor-stacking strategy studies<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 efeitos sobre press\u00e3o arterial, perfis lip\u00eddicos; dados de desfechos cardiovasculares acumulados dos programas de Fase 2\/3<\/li>\n<li><strong>Farmacologia do eixo do glucagon<\/strong> \u2014 farmacologia isolada do receptor de glucagon, din\u00e2mica da produ\u00e7\u00e3o hep\u00e1tica de glicose, caracteriza\u00e7\u00e3o do equil\u00edbrio de pot\u00eancia entre receptores de glucagon e GLP-1<\/li>\n<li><strong>Comparative incretin studies<\/strong> \u2014 compara\u00e7\u00e3o com agonista \u00fanico de GLP-1 (<a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a>) e farmacologia combinada do eixo da amilina (<a href=\"https:\/\/medsbase.com\/pt-br\/cagrilintide\/\">Cagrilintide<\/a> + Semaglutida CagriSema).<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre onde o survodutide se encaixa na paisagem de pept\u00eddeos metab\u00f3licos multi-agonistas, consulte <a href=\"https:\/\/medsbase.com\/pt-br\/mazdutide\/\">Mazdutide<\/a> como o co-agonista duplo GLP-1\/glucagon irm\u00e3o, <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> como o triagonista que adiciona GIP, <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">Tirzepatide<\/a> como a alternativa dual que utiliza GIP em vez de glucagon, e <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a> como a linha de base monoagonista. Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">cat\u00e1logo de pept\u00eddeos<\/a> para compostos relacionados. <\/p>\n<h2>Concentra\u00e7\u00f5es e Dosagens Dispon\u00edveis<\/h2>\n<p>MedsBase stocks Survodutide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de Uso T\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, titration arms<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo estendido, estudos de m\u00faltiplas coortes, menor custo por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 2 clinical doses are 0.3\u20134.8\u00a0mg weekly with a 4\u20136 month titration schedule, so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent multi-week supplies of clinical-equivalent dosing for in-vivo work. Survodutide is a comparatively scarce peptide because of active clinical development and Western-pharmaceutical supply-chain controls, which is reflected in the per-mg price relative to mature small synthetic peptides. <\/p>\n<h2>Como Comparar \u2014 Survodutida vs Mazdutida<\/h2>\n<p>Survodutida e <a href=\"https:\/\/medsbase.com\/pt-br\/mazdutide\/\">Mazdutide<\/a> are the two principal dual GLP-1 \/ glucagon co-agonist peptides in current literature. They share receptor pharmacology \u2014 both activate the GLP-1 and glucagon receptors, both lack GIP activity \u2014 but differ in structural origin, length, and engineered receptor-balance ratio. The comparison is one of the cleanest in current dual-agonist pharmacology because the receptor targets are identical and only the molecular implementation differs. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Survodutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Mazdutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perfil de receptor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucagon (dual)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucagon (dual)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Comprimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">29 amino\u00e1cidos (compacto)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~39 amino\u00e1cidos (derivado da oxintomodulina)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Desenvolvedor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Boehringer Ingelheim + Zealand Pharma<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Innovent Biologics (licenciado da Eli Lilly)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>C\u00f3digo de desenvolvimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">BI 456906<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">IBI362 \/ LY3305677<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Balan\u00e7o de receptores<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Prefer\u00eancia por glucagon (fortes efeitos hep\u00e1ticos)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Prefer\u00eancia por GLP-1 (perfil glic\u00eamico mais limpo)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 dias (semanal)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Semanal (acilado)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Sinal cl\u00ednico distintivo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Melhora da fibrose hep\u00e1tica por MASH (Fase 2)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Primeiro agonista duplo aprovado (China NMPA)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeito sobre o peso corporal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~19% (Fase 2, 46 semanas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15\u201317% (Fase 3, 48 semanas)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical studies weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0.3\u20134.8\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4\u20139\u00a0mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For MASH\/MASLD liver-disease studies, survodutide is the more frequently cited dual-agonist tool because of its distinctive Phase 2 hepatic-fibrosis signal. For studies interested in the glycaemic axis with minimal glucagon-pathway interference, mazdutide&#8217;s GLP-1-favoured balance is the cleaner choice. The two peptides together represent the principal Western (Boehringer-Zealand) and Eastern (Innovent) approaches to dual GLP-1\/glucagon co-agonist pharmacology \u2014 both are likely to remain in active studies and clinical development through this decade. <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138\u00a0\u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo n\u00e3o aberto, congele a \u221220\u00a0\u00b0C. O survodutide liofilizado \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 24 meses e a \u221220\u00a0\u00b0C por at\u00e9 36 meses. Evite ciclos de congelamento e descongelamento no p\u00f3 liofilizado. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.2\u00a0mL delivers 500\u00a0mcg; ~1.9\u00a0mL delivers a 4.8\u00a0mg clinical-equivalent dose. Swirl gently \u2014 do <strong>n\u00e3o<\/strong> sacuda \u2014 e permita 5\u201310 minutos para dissolu\u00e7\u00e3o completa (pept\u00eddeos acilados dissolvem-se mais lentamente do que pept\u00eddeos menores n\u00e3o modificados). Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda deve estar clara e incolor, sem part\u00edculas vis\u00edveis. <strong>Ap\u00f3s a reconstitui\u00e7\u00e3o:<\/strong> armazene refrigerado a 2\u20138 \u00b0C e use dentro de 30 dias para estabilidade ideal. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congelamento-descongelamento degradam a integridade do pept\u00eddeo. Descarte qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is Survodutide used for in studies?<\/h3>\n<p>Survodutide is used in studies investigating MASLD\/MASH liver disease (its strongest distinctive signal), obesity and body-composition regulation, type 2 diabetes preclinical models, energy-expenditure and thermogenesis, and comparative multi-agonist incretin pharmacology against single-agonist GLP-1, dual GLP-1\/GIP (tirzepatide), the sibling dual GLP-1\/glucagon mazdutide, and triple-agonist retatrutide. The pharmaceutical-grade survodutide sold here is <strong>n\u00e3o<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Como o Survodutide \u00e9 diferente do Mazdutide?<\/h3>\n<p>Both are dual GLP-1\/glucagon co-agonists with the same receptor targets, but they differ in structural origin and engineered receptor-balance ratio. Survodutide is a compact 29-amino-acid Boehringer-Zealand compound with a glucagon-favoured potency balance that produces particularly strong hepatic effects (the basis for its Phase 2 MASH signal). Mazdutide is a ~39-amino-acid oxyntomodulin-derived Innovent compound with a GLP-1-favoured balance that produces cleaner glycaemic effects. For MASH studies, survodutide is the canonical choice; for clean glycaemic-axis studies with minimal glucagon interference, mazdutide is preferred. <\/p>\n<h3>Como o Survodutide \u00e9 diferente do Tirzepatide?<\/h3>\n<p>Ambos s\u00e3o agonistas duplos de incretina, mas ativam receptores secund\u00e1rios diferentes. O Tirzepatide \u00e9 GLP-1 + GIP (~22% de efeito no peso corporal no estudo SURMOUNT-1). O Survodutide \u00e9 GLP-1 + glucagon (~19% na Fase 2). As duas combina\u00e7\u00f5es de receptores produzem perfis metab\u00f3licos qualitativamente diferentes: o GIP adiciona lip\u00f3lise em adip\u00f3citos em condi\u00e7\u00f5es de jejum; o glucagon adiciona gasto energ\u00e9tico substancial e mobiliza\u00e7\u00e3o de lip\u00eddios hep\u00e1ticos. O Survodutide tem o sinal \u00fanico de fibrose MASH devido ao seu efeito hep\u00e1tico impulsionado pelo glucagon. <\/p>\n<h3>Como o Survodutide \u00e9 diferente do Retatrutide?<\/h3>\n<p>Retatrutide adds GIP receptor activation on top of GLP-1 + glucagon \u2014 it is a triple agonist. Survodutide stops at the dual combination. Retatrutide&#8217;s Phase 2 body-weight effect (~24%) is larger than survodutide&#8217;s (~19%), suggesting GIP adds substantial benefit. Survodutide has the stronger MASH signal in its respective Phase 2 trial. For studies isolating the dual GLP-1 + glucagon combination without the GIP confound, survodutide (and mazdutide) are the cleaner tools. <\/p>\n<h3>What is the typical Survodutide dose?<\/h3>\n<p>Published Phase 2 clinical protocols use weekly subcutaneous dosing with a long titration schedule starting at 0.3\u00a0mg and stepping through 0.9, 1.8, 2.4, 3.6 to a maintenance dose of 4.8\u00a0mg weekly over approximately 24 weeks. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 ~1.9\u00a0mL equals a 4.8\u00a0mg clinical-equivalent dose. <\/p>\n<h3>O Survodutide \u00e9 aprovado pela FDA?<\/h3>\n<p>No. Survodutide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Phase 3 trials for obesity and MASH are ongoing as of current literature. <\/p>\n<h3>Como o Survodutide deve ser armazenado?<\/h3>\n<p>Frascos liofilizados: refrigerados a 2\u20138 \u00b0C para estoque de trabalho em curto prazo, ou \u221220 \u00b0C para armazenamento em longo prazo de frascos n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138 \u00b0C, usar dentro de 30 dias. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congelamento e descongelamento degradam o pept\u00eddeo. Proteja da luz direta em todos os momentos. <\/p>\n<h3>Como devo reconstituir o Survodutide?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o p\u00f3 liofilizado), agite suavemente e aguarde 5\u201310 minutos para dissolu\u00e7\u00e3o completa (pept\u00eddeos acilados dissolvem-se mais lentamente do que pept\u00eddeos menores n\u00e3o modificados). N\u00e3o <strong>n\u00e3o<\/strong> Agite o frasco. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 clara e incolor. Para um frasco de 5 mg + 2,0 mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 2,5 mg\/mL. <\/p>\n<h3>Quais dosagens a MedsBase oferece?<\/h3>\n<p>MedsBase carries Survodutide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Why is Survodutide particularly relevant for MASH studies?<\/h3>\n<p>Survodutide&#8217;s glucagon-favoured dual-receptor balance produces especially strong hepatic effects in published studies. Hepatocytes are highly enriched for glucagon receptors, so glucagon-pathway activation directly drives fatty-acid oxidation and triglyceride export from steatotic liver. Combined with the GLP-1 arm&#8217;s indirect benefits via reduced insulin resistance, the dual effect on the liver translates into the striking MASH-fibrosis-stage improvement reported in the Phase 2 trial \u2014 an outcome that distinguished survodutide from other dual and triple agonists at comparable body-weight effects. <\/p>\n<h3>O componente glucagon causa hiperglicemia?<\/h3>\n<p>O cl\u00e1ssico \u201cparadoxo do glucagon\u201d se aplica ao survodutide, assim como a outros co-agonistas duplos GLP-1\/glucagon: o glucagon sozinho aumenta a glicose ao estimular a produ\u00e7\u00e3o hep\u00e1tica de glicose, mas a a\u00e7\u00e3o dominante de redu\u00e7\u00e3o da glicose do componente GLP-1 na insulina e na supress\u00e3o do glucagon nas c\u00e9lulas beta e alfa supera isso. A propor\u00e7\u00e3o de equil\u00edbrio de receptor projetada do Survodutide alcan\u00e7a uma redu\u00e7\u00e3o l\u00edquida da glicose, apesar da ativa\u00e7\u00e3o do receptor de glucagon \u2014 dados publicados da Fase 2 confirmam um controle glic\u00eamico melhorado em coortes de T2DM na dose de manuten\u00e7\u00e3o. <\/p>\n<h3>Does Survodutide cause side reported effects?<\/h3>\n<p>O achado mais consistente \u00e9 gastrointestinal, semelhante a outros pept\u00eddeos do eixo GLP-1 \u2014 n\u00e1usea, supress\u00e3o transit\u00f3ria do apetite e esvaziamento g\u00e1strico retardado s\u00e3o dose-dependentes e tendem a se atenuar com o longo esquema de titula\u00e7\u00e3o usado na Fase 2. Achados relacionados ao componente glucagon incluem eleva\u00e7\u00f5es modestas na frequ\u00eancia card\u00edaca em repouso e (raramente) efeitos transit\u00f3rios na press\u00e3o arterial. A longa titula\u00e7\u00e3o \u00e9 parcialmente projetada para minimizar esses efeitos. <\/p>\n<h3>Qual \u00e9 a meia-vida do Survodutide?<\/h3>\n<p>In preclinical and clinical studies, survodutide has a plasma half-life of approximately 6 days following subcutaneous administration, comparable to tirzepatide (~5 days) and slightly shorter than semaglutide (~7 days). The half-life is achieved by reversible binding to circulating serum albumin via the fatty-acid acyl tether at a lysine residue. <\/p>\n<h3>How long does Survodutide take to show effects in preclinical studies?<\/h3>\n<p>Os efeitos farmacodin\u00e2micos agudos na toler\u00e2ncia \u00e0 glicose e no esvaziamento g\u00e1strico s\u00e3o detect\u00e1veis dentro de horas ap\u00f3s a primeira dose. Os efeitos no peso corporal em modelos de roedores DIO geralmente se tornam estatisticamente significativos ap\u00f3s 1\u20132 semanas de dosagem semanal. Os efeitos de MASLD\/MASH no conte\u00fado de triglicer\u00eddeos hep\u00e1ticos e na normaliza\u00e7\u00e3o de ALT\/AST se acumulam ao longo de 8\u201316 semanas de dosagem regular. O efeito m\u00e1ximo na composi\u00e7\u00e3o corporal se desenvolve ao longo de 24\u201346 semanas, espelhando a trajet\u00f3ria da Fase 2. <\/p>\n<h3>Posso encomendar Survodutide para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia Survodutide para todo o mundo a partir de nossa rede dedicada de envio de pept\u00eddeos. Pedidos exclusivos de pept\u00eddeos se qualificam para nosso servi\u00e7o de envio de pept\u00eddeos independente. Todos os pedidos s\u00e3o enviados em embalagens com controle de temperatura com rastreamento completo e s\u00e3o cobertos por nossa <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Reenvio Garantido<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, MASH, and Multi-Agonist Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/mazdutide\/\"><strong>Mazdutide<\/strong><\/a> \u2014 Co-agonista duplo GLP-1\/glucagon irm\u00e3o \u2014 propor\u00e7\u00e3o alternativa de equil\u00edbrio de receptor<\/li>\n<li><a href=\"\/pt-br\/retatrutide\/\"><strong>Retatrutida<\/strong><\/a> \u2014 Agonista triplo GLP-1\/GIP\/glucagon \u2014 adiciona GIP ao perfil duplo GLP-1\/glucagon<\/li>\n<li><a href=\"\/pt-br\/tirzepatide\/\"><strong>Tirzepatide<\/strong><\/a> \u2014 Agonista duplo de GLP-1\/GIP \u2014 alternativa de agonista duplo utilizando GIP em vez de glucagon<\/li>\n<li><a href=\"\/pt-br\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Agonista \u00fanico de GLP-1 \u2014 comparador de linha de base can\u00f4nico<\/li>\n<li><a href=\"\/pt-br\/cagrilintide\/\"><strong>Cagrilintide<\/strong><\/a> \u2014 An\u00e1logo de amilina \u2014 abordagem alternativa de farmacologia combinada<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore o cen\u00e1rio de co-agonista duplo GLP-1\/glucagon<\/strong><\/p>\n<p style=\"margin: 0;\">Navegue pela categoria completa <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\"><strong>cat\u00e1logo de pept\u00eddeos<\/strong><\/a>, com compostos multi-agonistas relacionados incluindo <a href=\"https:\/\/medsbase.com\/pt-br\/mazdutide\/\">Mazdutide<\/a> (co-agonista duplo GLP-1\/glucagon), <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> (triplo-agonista), e <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">Tirzepatide<\/a> (duplo GLP-1\/GIP). Guia comparativo: <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide-vs-tirzepatide\/\">Retatrutida vs Tirzepatida \u2014 agonista triplo vs dual<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Coagonista dual de receptor GLP-1 + glucagon<br \/>\n\u2705 Pept\u00eddeo compacto de 29-aa Boehringer\/Zealand (BI 456906)<br \/>\n\u2705 Forte sinal de fibrose hep\u00e1tica MASH na Fase 2<br \/>\n\u2705 Equil\u00edbrio de receptor favorecido pelo glucagon<br \/>\n\u2705 Dosagem semanal (~6 dias de meia-vida)<\/p>\n<p><strong>Survodutide<\/strong> cont\u00e9m composto de pept\u00eddeo sint\u00e9tico.<\/p>","protected":false},"featured_media":70984,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5441,6286],"class_list":["post-70759","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-peptide","product_tag-survodutide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/70759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=70759"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/70984"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=70759"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=70759"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=70759"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=70759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}